title: Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
abstract: OBJECTIVE
  Colorectal cancer (CRC) is among the most common malignancies worldwide. Understanding CRC prognosis at the initial diagnosis is very important for therapeutic strategy selection. This study was conducted to evaluate the prognostic value of preoperative serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) for predicting 5-year recurrence-free survival (RFS) in CRC patients.
  
  
  METHODS
  Preoperative serum CA19-9, CEA and CA125 levels were detected by C12 protein chip diagnostic system in 103 patients with CRC, and their correlations with the 5-year RFS were analyzed.
  
  
  RESULTS
  Patients with positive preoperative serum CA19-9, CEA and CA125 had higher 5-year recurrent rates (75.0% vs 41.0%, 65.6% vs 39.4%, and 87.5% vs 44.2% respectively, all p< (o)0.05), and reduced median RFS (14 vs 35 months, 20 vs 36 months, and 4 vs 35 months respectively, all p< (o)0.05) compared with patients negative for corresponding tumor marker (TM). The median RFS was 59 months (95% CI 28.9-89.1 months) with negative TMs, 14 months (95% CI 4.5-23.5) for 1~2 positive TMs, and 4 months (95% CI 2.4-5.6) for all 3 positive TMs. Patients with simultaneously positive serum CA19-9, CEA and CA125 had the highest recurrence rate (100%) and the shortest RFS (median 4 months). Univariate analysis showed that stage and the preoperative single TM or combined TMs correlated with RFS, whereas multivariate Cox regression model analysis revealed only stage and preoperative serum status of CEA+CA19-9+CA125 to be independent prognostic factors.
  
  
  CONCLUSIONS
  Preoperative serum CA19-9+CEA+CA125 can be used an independent prognostic factor for CRC 5-year RFS.
authors.affiliation: Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory on Tumor Biological Behavior and Hubei Cancer Clinical Study Center, Wuhan, China.
authors.forename: Xue-Qin
authors.initials: XQ
authors.lastname: Yang
authors.forename: Chuang
authors.initials: C
authors.lastname: Chen
authors.forename: Fu-Bing
authors.initials: FB
authors.lastname: Wang
authors.forename: Chun-Wei
authors.initials: CW
authors.lastname: Peng
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen